DDInter255 DDInter178
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
Busulfan {u} (Compound) binds {v} (Gene) MGST2
Busulfan {u} (Compound) upregulates {v} (Gene) DUSP11
Busulfan {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Busulfan {u} (Compound) downregulates {v} (Gene) MRPL19
Busulfan {u} (Compound) causes {v} (Side Effect) Dermatitis bullous
Busulfan (Compound) treats hematologic cancer (Disease)
Busulfan (Compound) binds MGST2 (Gene)
Busulfan (Compound) upregulates DUSP11 (Gene)
Busulfan (Compound) is included by Alkylating Activity (Pharmacologic Class)
Busulfan (Compound) downregulates MRPL19 (Gene)
Busulfan (Compound) causes Dermatitis bullous (Side Effect)